Overview

Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery

Status:
Completed

Trial end date:
2018-10-25

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Antibodies, Blocking
Antibodies, Monoclonal

Criteria

Inclusion Criteria:

Must have X-ray confirmed successful hip fracture repair; Must have completed surgical
wound healing; Ability to walk a specified distance with or without a walking aid; Must
weigh at least 35 kg.

Exclusion Criteria:

Must not have history of any other lower limb fractures in the past 6 months; Must not have
certain cardiovascular conditions; Must not have a chronic active infection (e.g. HIV,
hepatitis B or C, etc); Must not have used high-dose corticosteroid medications for at
least 3 months in the past year;